A New Wave of Progress in the Treatment of Renal Cell Carcinoma: Highlights from ASCO GU 2023 and Beyond
EP. 1: Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD Moshe Ornstein, MD, MA, starts a conversation on how patients with metastatic renal cell carcinoma are classified by risk, and how risk category influences approaches to systemic therapy.
EP. 2: Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD Mehmet Asim Bilen, MD, presents a profile of a 65-year-old woman with metastatic renal cell carcinoma for discussion.
EP. 3: Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.
EP. 4: Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.
EP. 5: Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD The panel discusses the use of quality-of-life clinical trial data in metastatic renal cell carcinoma and how liver and brain metastases affect treatment decision-making.
EP. 6: Treatment Approaches for Patients with RCC and Bone Metastases
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD Mehmet Asim Bilen, MD, details how he approaches IO/TKI therapy for patients with renal cell carcinoma with bone metastases.
EP. 7: Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD The panel provides an overview of novel double combination therapies currently under investigation.
EP. 8: Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD Drs Moshe Ornstein and Hans Hammers review data from the COSMIC-313 trial investigating ipilimumab, nivolumab, and cabozantinib for the frontline treatment of metastatic renal cell carcinoma.
EP. 9: Updates in the Adjuvant Treatment of Metastatic RCC
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD The panel discusses recent clinical trial data in the adjuvant treatment of metastatic renal cell carcinoma.
EP. 10: Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD Hans Hammers, MD, presents a profile of a 47-year-old male with refractory renal cell carcinoma.
EP. 11: Preferred Treatment Regimens for Refractory RCC
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD The panel shares their preferred treatment regimens for patients with refractory renal cell carcinoma.
EP. 12: Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD The panel discusses the best approaches to treating patients with non-clear cell RCC.
EP. 13: Genetic Counseling for Patients with Non-Clear Cell RCC
ByKathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA,Mehmet Asim Bilen, MD, Emory University School of Medicine,Hans Hammers, MD, PhD The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.
